Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
A word on why once daily is the anchoring frequency rather than something more elaborate
Symptoms include difficulty breathing, facial or throat swelling, rapid heartbeat, hives, and a sudden drop in blood pressure
If you take insulin, sulfonylureas, or meglitinides, your doses will likely require reduction to prevent hypoglycemia
see NHS guidance and Xenical/Alli SmPCs), and injectable GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda)